Distribution of factors between hierarchical cluster-defined CBF subgroups
| Factors at diagnosis . | Group I; n = 35 . | Group II; n = 58 . | P . |
|---|---|---|---|
| Sex | |||
| Male, no. (%) | 19/35 (54) | 40/58 (69) | — |
| Female, no. (%) | 16/35 (46) | 18/58 (31) | ns |
| Age | |||
| No. of patients | 34 | 55 | — |
| Median, y (range) | 46 (19-72) | 47 (19-73) | ns |
| FAB subtype | |||
| M2 (%) | 6/32 (19) | 19/53 (36) | ns |
| M4 (%) | 22/32 (69) | 25/53 (47) | — |
| Other (%) | 4/32 (12) | 9/53 (17) | — |
| WBC | |||
| No. of patients | 32 | 55 | — |
| Median, × 109/L (range) | 42 (2-157) | 18 (2-152) | .011 |
| Median in t(8;21), × 109/L (range) | 18 (2-130) | 12 (2-152) | ns |
| Median in inv(16), × 109/L (range) | 47 (2-157) | 29 (2-137) | .057 |
| BM blast | |||
| No. of patients | 29 | 45 | — |
| Median, % (range) | 68 (25-100) | 70 (6-98) | ns |
| Cytogenetic group | |||
| t(8;21) (%) | 9/35 (26) | 29/58 (50) | — |
| inv(16) (%) | 26/35 (74) | 29/58 (50) | .035 |
| Additional cytogenetic aberrations | |||
| None (%) | 22/34 (65) | 25/55 (45) | ns |
| Trisomy 8 (%) | 3/34 (9) | 8/55 (15) | ns |
| del(9q)/-9 (%) | 1/34 (3) | 2/55 (4) | ns |
| Trisomy 22 (%) | 2/34 (6) | 4/55 (7) | ns |
| -Y/males (%) | 3/18 (17) | 13/38 (34) | ns |
| -X/females (%) | 0/16 (0) | 5/17 (29) | .019 |
| Other (%) | 6/34 (18) | 9/55 (16) | ns |
| Molecular genetic aberrations | |||
| FLT3-ITD (%) | 4/28 (14) | 0/52 (0) | .026 |
| FLT3-TKD (%) | 4/27 (15) | 5/49 (10) | ns |
| KIT mutation (%) | 3/24 (13) | 10/41 (24) | ns |
| Exon 8 (%) | 1/24 (4) | 5/41 (12) | ns |
| Exon 17 (%) | 2/24 (8) | 5/41 (12) | ns |
| NRAS mutation (%) | 5/19 (26) | 13/41 (32) | ns |
| Exon 1 (%) | 1/19 (5) | 7/41 (17) | ns |
| Exon 2 (%) | 4/19 (21) | 6/41 (15) | ns |
| Fusion gene transcript no. at diagnosis | |||
| No. of patients | 19 | 30 | — |
| Median (range) | 52702 (537-11863009) | 53746 (6477-1775159) | ns |
| Factors at diagnosis . | Group I; n = 35 . | Group II; n = 58 . | P . |
|---|---|---|---|
| Sex | |||
| Male, no. (%) | 19/35 (54) | 40/58 (69) | — |
| Female, no. (%) | 16/35 (46) | 18/58 (31) | ns |
| Age | |||
| No. of patients | 34 | 55 | — |
| Median, y (range) | 46 (19-72) | 47 (19-73) | ns |
| FAB subtype | |||
| M2 (%) | 6/32 (19) | 19/53 (36) | ns |
| M4 (%) | 22/32 (69) | 25/53 (47) | — |
| Other (%) | 4/32 (12) | 9/53 (17) | — |
| WBC | |||
| No. of patients | 32 | 55 | — |
| Median, × 109/L (range) | 42 (2-157) | 18 (2-152) | .011 |
| Median in t(8;21), × 109/L (range) | 18 (2-130) | 12 (2-152) | ns |
| Median in inv(16), × 109/L (range) | 47 (2-157) | 29 (2-137) | .057 |
| BM blast | |||
| No. of patients | 29 | 45 | — |
| Median, % (range) | 68 (25-100) | 70 (6-98) | ns |
| Cytogenetic group | |||
| t(8;21) (%) | 9/35 (26) | 29/58 (50) | — |
| inv(16) (%) | 26/35 (74) | 29/58 (50) | .035 |
| Additional cytogenetic aberrations | |||
| None (%) | 22/34 (65) | 25/55 (45) | ns |
| Trisomy 8 (%) | 3/34 (9) | 8/55 (15) | ns |
| del(9q)/-9 (%) | 1/34 (3) | 2/55 (4) | ns |
| Trisomy 22 (%) | 2/34 (6) | 4/55 (7) | ns |
| -Y/males (%) | 3/18 (17) | 13/38 (34) | ns |
| -X/females (%) | 0/16 (0) | 5/17 (29) | .019 |
| Other (%) | 6/34 (18) | 9/55 (16) | ns |
| Molecular genetic aberrations | |||
| FLT3-ITD (%) | 4/28 (14) | 0/52 (0) | .026 |
| FLT3-TKD (%) | 4/27 (15) | 5/49 (10) | ns |
| KIT mutation (%) | 3/24 (13) | 10/41 (24) | ns |
| Exon 8 (%) | 1/24 (4) | 5/41 (12) | ns |
| Exon 17 (%) | 2/24 (8) | 5/41 (12) | ns |
| NRAS mutation (%) | 5/19 (26) | 13/41 (32) | ns |
| Exon 1 (%) | 1/19 (5) | 7/41 (17) | ns |
| Exon 2 (%) | 4/19 (21) | 6/41 (15) | ns |
| Fusion gene transcript no. at diagnosis | |||
| No. of patients | 19 | 30 | — |
| Median (range) | 52702 (537-11863009) | 53746 (6477-1775159) | ns |
ns indicates not significant; —, not applicable.